Eight days versus weekly intramuscular methotrexate for the treatment of low-risk gestational trophoblastic neoplasia

Objectives: To compare the efficacy of weekly and eight-day methotrexate (MTX) regimens for the treatment of low-risk gestational trophoblastic neoplasia (GTN). Toxicity profiles, patient satisfaction, and treatment duration were also considered for future implications. Materials and Methods: This randomized controlled trial included all patients diagnosed with low-risk gestational trophoblastic neoplasia at King Abdulaziz University Hospital over a period of four years. The primary remission rate, duration of treatment, number of treatment cycles, as well as toxicity and the change of the chemotherapeutic agent were compared following either a weekly methotrexate regimen (IM, 50 mg/m2 ) or an eight-day regimen (1 mg/kg IM every other day for four doses) and leucovorin calcium (0.1 mg/kg, given once, 24 hours after each dose). Results: Sixty patients (34 in the weekly IM group) were included. The eight-day protocol was associated with lesser treatment cycles (p = 0.011) and higher total methotrexate dose (p < 0.001) when compared to the weekly regimen. The eight-day protocol showed a relatively higher primary success rate when compared to the weekly protocol (84.6% vs. 70.6%), although this difference failed to reach statistical significance (p = 0.235). Only two cases of hepatotoxicity were reported in the single weekly group and no toxicity was reported in the eight-day group. Conclusion: The eight-day regimen was superior to the weekly regimen in terms of the remission rate, treatment duration, and toxicity profiles. Future studies should be based on larger sample size, investigate methotrexate effects on fertility, and the risk factors that may lead to methotrexate resistance.

Low-risk gestational trophoblastic neoplasia (GTN); Methotrexate; Success rate.

[1] Seckl M.J., Sebire N.J., Berkowitz R.S.: “Gestational trophoblastic disease”. Lancet, 2010, 376, 717.

[2] Eysbouts Y., Bulten J., Ottevanger P., Thomas C.M., Ten KateBooij M.J., van Herwaarden A.E., et al.: “Trends in incidence for gestational trophoblastic disease over the last 20 years in a population - based study”. Gynecol. Oncol., 2016, 140, 70.

[3] Berkowitz R.S., Goldstein D.P.: “Clinical practice. Molar pregnancy”. N. Engl. J. Med., 2009, 360, 1639.

[4] Chattopadhyay S.K., Sengupta B.S., al-Ghreimil M., Edrees Y.B., Lambourne A., et al.: “Epidemiologic study of gestational trophoblastic diseases in Saudi Arabia”. Surg. Gynecol. Obstet., 1988, 167, 393.

[5] Anfinan N., Sait K., Sait H.: “Gestational trophoblastic disease in the western region of Saudi Arabia (single-institute experience)”. Eur. J. Obstet. Gynecol. Reprod. Biol., 2014, 180, 8.

[6] Hui P.: “Gestational Trophoblastic Disease: General Aspects”. In: Hui P, (eds). Gestational trophoblastic disease: diagnostic and molecular genetic pathology. London: Springer Science & Business Media;, 2011, 1.

[7] Tavassoli F., Peter D.: “World Health Organization: tumours of the breast and female genital organs” Lyon: IARC Press, 2004. Available at: https://www.iarc.fr/en/publications/pdfs-online/patgen/bb4/ BB4.pdf.

[8] FIGO Oncology Committee: “FIGO staging for gestational trophoblastic neoplasia 2000”. Int. J. Gynaecol. Obstet., 2002, 77, 285.

[9] Biscaro A., Braga A., Berkowitz R.S.: “Diagnosis, classification and treatment of gestational trophoblastic neoplasia”. Rev. Bras. Ginecol. Obstet., 2015, 37, 42.

[10] Foulmann K., Guastalla J-P., Caminet N., Trillet-Lenoir V., Raudrant D., Golfier F., Schott A.M.: “What is the best protocol of single-agent methotrexate chemotherapy in nonmetastatic or lowrisk metastatic gestational trophoblastic tumors? A review of the evidence”. Gynecol. Oncol., 2006, 102, 103.

[11] Van Trommel N.E., Sweep F.C., Schijf C.P., Massuger L.F., Thomas C.M.: “Diagnosis of hydatidiform mole and persistent trophoblastic disease: diagnostic accuracy of total human chorionic gonadotropin (hCG), free hCG α-and β-subunits, and their ratios”. Eur. J. Endocrinol., 2005, 153, 565.

[12] Ngan H., Kohorn E.I., Cole L.A., Kurman R.J., Kim S.J., Lurain J.R., et al.: “Trophoblastic disease”. Int. J. Gynaecol. Obstet., 2012, 119, 130.

[13] Mangili G., Lorusso D., Brown J., Pfisterer J., Massuger L., Vaughan M., et al.: “Trophoblastic disease review for diagnosis and management: a joint report from the International Society for the Study of Trophoblastic Disease, European Organisation for the Treatment of Trophoblastic Disease, and the Gynecologic Cancer InterGroup”. Int. J. Gynecol. Cancer, 2014, 24, S109.

[14] Hancock B.W., Nazir K., Everard J.E.: “Persistent gestational trophoblastic neoplasia after partial hydatidiform mole incidence and outcome”. J. Reprod. Med., 2006, 51, 764.

[15] Brown J., Naumann R.W., Seckl M.J., Schink J.: “15 years of progress in gestational trophoblastic disease: Scoring, standardization, and salvage”. Gynecol. Oncol., 2017, 144, 200.

[16] Osborne R.J., Filiaci V., Schink J.C., Mannel R.S., Alvarez Secord A., Kelley J.L., et al.: “Phase III trial of weekly methotrexate or pulsed dactinomycin for low-risk gestational trophoblastic neoplasia: a gynecologic oncology group study”. J. Clin. Oncol., 2011, 29, 825.

[17] Sita-Lumsden A., Short D., Lindsay I., Sebire N.J., Adjogatse D., Seckl M.J., et al.: “Treatment outcomes for 618 women with gestational trophoblastic tumours following a molar pregnancy at the Charing Cross Hospital, 2000–2009”. Br. J. Cancer, 2012, 107, 1810.

[18] McNeish I.A., Strickland S., Holden L., Rustin G.J., Foskett M., Seckl M.J., et al.: “Low-risk persistent gestational trophoblastic disease: outcome after initial treatment with low-dose methotrexate and folinic acid from 1992 to 2000”. J. Clin. Oncol., 2002, 20, 1838.

[19] Bagshawe K.D., Dent J., Newlands E.S., Begent R.H., Rustin G.J.: “The role of low-dose methotrexate and folinic acid in gestational trophoblastic tumours (GTT)”. Br. J. Obstet. Gynaecol., 1989, 96, 795.

[20] Gleeson N., Finan M., Fiorica J., Robert W.S., Hoffman M.S., Wilson J.: “Nonmetastatic gestational trophoblastic disease. Weekly methotrexate compared with 8-day methotrexate-folinic acid”. Eur.J. Gynaecol. Oncol., 1993, 14, 461.

[21] Wong L., Choo Y., Ma H.: “Methotrexate with citrovorum factor rescue in gestational trophoblastic disease”. Am. J.Obstetr. Gynecol., 1985, 152, 59.

[22] Lertkhachonsuk A.A., Israngura N., Wilailak S., Tangtrakul S.: “Actinomycin d versus methotrexate-folinic acid as the treatment of stage I, low-risk gestational trophoblastic neoplasia: a randomized controlled trial”. Int. J. Gynecol. Cancer, 2009, 19, 985.

[23] Stevens F., Katzorke N., Tempfer C., Kreimer U., Bizjak G.I., Fleisch M.C., et al.: “Gestational trophoblastic disorders: an update in 2015”. Geburtshilfe Frauenheilkd., 2015, 75, 1043.

[24] National Cancer Institute: “Common Terminology Criteria for Adverse Events (CTCAE) - Protocol Development - CTEP: NCI; 2017”. Available at: https://ctep.cancer.gov/protocoldevelopment/ electronic_applications/ctc.htm.

[25] Li M.C., Hertz R., Spencer D.B.: “Effect of methotrexate therapy upon choriocarcinoma and chorioadenoma”. Proc. Soc. Exp. Biol. Med., 1956, 93, 361.

[26] Skubisz M.M., Tong S.: “The evolution of methotrexate as a treatment for ectopic pregnancy and gestational trophoblastic neoplasia: a review”. ISRN Obstet. Gynecol., 2012, 2012, 637094.

[27] Bleyer W.A.: “The clinical pharmacology of methotrexate. New applications of an old drug”. Cancer, 1978, 41, 36.

[28] Homesley H.D., Blessing J.A., Rettenmaier M., Capizzi R.L., Major F.J., Twiggs L.B.: “Weekly intramuscular methotrexate for non-metastatic gestational trophoblastic disease”. Obstet. Gynecol., 1988, 72, 413.

[29] Goldstein D.P., Winig P., Shirley R.L.: “Actinomycin D As Initial Therapy Of Gestational Trophoblastic Disease: A Reevaluation”. Obstet. Gynecol., 1972, 39, 341.

[30] Kang W.D., Choi H.S., Kim S.M.: “Weekly methotrexate (50mg/m(2)) without dose escalation as a primary regimen for lowrisk gestational trophoblastic neoplasia”. Gynecol. Oncol., 2010, 117, 477.

[31] Wu J.J., Feldman S.R., Lebwohl M.G.: ”Chapter 4- Methotrexate”.Therapy for Severe Psoriasis. Los Angeles (USA): Elsevier, 2016, 37.

[32] Bath R.K., Brar N.K., Forouhar F.A., Wu G.Y.: “A review of methotrexate-associated hepatotoxicity”. J. Dig. Dis., 2014, 15, 517.

[33] Berkowitz R.S., Goldstein D.P., Bernstein M.R.: “Ten year’s experience with methotrexate and folinic acid as primary therapy for gestational trophoblastic disease”. Gynecol. Oncol., 1986, 23, 111.

[34] Smith E.B., Weed J.C., Tyrey L., Hammond C.B.: “Treatment of nonmetastatic gestational trophoblastic disease: results of methotrexate alone versus methotrexate-folinic acid”. Am. J. Obstet. Gynecol., 1982, 144, 88.

[35] Rotmensch J., Rosenshein N., Donehower R., Dillon M., Villar J.: “Plasma methotrexate levels in patients with gestational trophoblastic neoplasia treated by two methotrexate regimens”. Am. J. Obstet. Gynecol., 1984, 148, 730.